Cargando…

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies

OBJECTIVE: Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiller, Emmanuelle, Weiss, Catherine, Watling, Christopher P, Edge, Christopher, Hobart, Mary, Eriksson, Hans, Fava, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751804/
https://www.ncbi.nlm.nih.gov/pubmed/29343962
http://dx.doi.org/10.2147/NDT.S146840
_version_ 1783290022479265792
author Weiller, Emmanuelle
Weiss, Catherine
Watling, Christopher P
Edge, Christopher
Hobart, Mary
Eriksson, Hans
Fava, Maurizio
author_facet Weiller, Emmanuelle
Weiss, Catherine
Watling, Christopher P
Edge, Christopher
Hobart, Mary
Eriksson, Hans
Fava, Maurizio
author_sort Weiller, Emmanuelle
collection PubMed
description OBJECTIVE: Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. METHODS: This was a systematic literature review of articles in any language from the MEDLINE database published between January 1990 and March 2017. Eligible studies met the following criteria: patients with MDD; inadequate response to at least one ADT; adjunctive therapy (pharmacological or otherwise) to ADT; placebo control group; randomized controlled trial or a post hoc analysis of a randomized controlled trial; reported a self-rated functioning scale. Study characteristics and functioning efficacy data were extracted. RESULTS: A total of 2,090 discrete records were screened, 293 full-text articles were assessed for eligibility, and 26 studies were included. All studies were acute (6–12 weeks) except for one 52-week study. The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS). Of the 13 adjunctive agents identified, aripiprazole, brexpiprazole, edivoxetine, and risperidone improved functioning versus placebo (p<0.05), as measured by the SDS total or mean score. On the SDS “work/studies” item, only aripiprazole had a statistically significant benefit, in one study out of four. Thus, where a benefit was observed on the SDS total or mean, this was generally driven by improvement on the “social life” and “family life” items. A limitation of the review is that it only considered published literature from one database. CONCLUSION: The SDS, a self-rated functional measure, is informative in acute randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. However, the item that measures work performance may be less relevant to this population than the items that measure social and family life.
format Online
Article
Text
id pubmed-5751804
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57518042018-01-17 Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies Weiller, Emmanuelle Weiss, Catherine Watling, Christopher P Edge, Christopher Hobart, Mary Eriksson, Hans Fava, Maurizio Neuropsychiatr Dis Treat Review OBJECTIVE: Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. METHODS: This was a systematic literature review of articles in any language from the MEDLINE database published between January 1990 and March 2017. Eligible studies met the following criteria: patients with MDD; inadequate response to at least one ADT; adjunctive therapy (pharmacological or otherwise) to ADT; placebo control group; randomized controlled trial or a post hoc analysis of a randomized controlled trial; reported a self-rated functioning scale. Study characteristics and functioning efficacy data were extracted. RESULTS: A total of 2,090 discrete records were screened, 293 full-text articles were assessed for eligibility, and 26 studies were included. All studies were acute (6–12 weeks) except for one 52-week study. The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS). Of the 13 adjunctive agents identified, aripiprazole, brexpiprazole, edivoxetine, and risperidone improved functioning versus placebo (p<0.05), as measured by the SDS total or mean score. On the SDS “work/studies” item, only aripiprazole had a statistically significant benefit, in one study out of four. Thus, where a benefit was observed on the SDS total or mean, this was generally driven by improvement on the “social life” and “family life” items. A limitation of the review is that it only considered published literature from one database. CONCLUSION: The SDS, a self-rated functional measure, is informative in acute randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. However, the item that measures work performance may be less relevant to this population than the items that measure social and family life. Dove Medical Press 2017-12-29 /pmc/articles/PMC5751804/ /pubmed/29343962 http://dx.doi.org/10.2147/NDT.S146840 Text en © 2018 Weiller et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Weiller, Emmanuelle
Weiss, Catherine
Watling, Christopher P
Edge, Christopher
Hobart, Mary
Eriksson, Hans
Fava, Maurizio
Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_full Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_fullStr Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_full_unstemmed Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_short Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
title_sort functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751804/
https://www.ncbi.nlm.nih.gov/pubmed/29343962
http://dx.doi.org/10.2147/NDT.S146840
work_keys_str_mv AT weilleremmanuelle functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies
AT weisscatherine functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies
AT watlingchristopherp functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies
AT edgechristopher functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies
AT hobartmary functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies
AT erikssonhans functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies
AT favamaurizio functioningoutcomeswithadjunctivetreatmentsformajordepressivedisorderasystematicreviewofrandomizedplacebocontrolledstudies